BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations

April 13, 2017
Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications. NOX-A12 is designed to enhance the effectiveness of anti-cancer treatments, including immuno-oncology approaches such as immune checkpoint inhibitors and current standards of care such as chemotherapy and radiotherapy, without adding significant new side effects for patients. Mangasarian told Scrip the ideal partner for Noxxon currently would be one that could offer a potential cancer drug for combination with its pipeline therapeutics, as well as financial backing.
Previous Article
Report findings provide insight into technological innovations and trends in drug development
Report findings provide insight into technological innovations and trends in drug development

Knect365 Life Sciences has released a report offering unique insights into the awareness, perceptions and i...

Next Video
BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies
BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies

Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR...